Chasing END TB 2025: Arithmetic needed for logistics!

India adopted changes in NTEP (Erstwhile RNTCP, Revised National TB Program, renamed as National TB Elimination Program) in the recent years with an aim to End TB by 2025 way ahead of the global target of ending TB by 2030. It is taking a long time for the changes to trickle down to the grass root level to change the behavior of the ground level force to understand and adopt to the changes that are being ordered and several other changes that are being pushed to the field in tandem. This has made field workers to be on their toes to understand and implement all the changes. The logistics like referral forms, GeneXpert/CBNAAT cartridges, slides etc., required for the program need to be calculated and used as per the changes. Shortages in the procurement or indenting will result in hampering the smooth functioning of the program. Accordingly, we calculated the logistics required for the patients estimated to occur in an area depending on the previous year's patient load. The breakup of the patients was adopted from the available references given. Also, the 2019 data of the load of different type of patients in India and the world were also taken. Total logistics were calculated for two hundred patients. Based on the calculations, a generic formula was derived. When the total number of patients in the previous year/quarter/or any period is N, then below is the formula which can estimate the required logistics for the next similar period.

How do patients who fail first-line TB treatment but who are not placed on an MDR-TB regimen fare in South India?

SETTING: Seven districts in Andhra Pradesh, South India. OBJECTIVES: To a) determine treatment outcomes of patients who fail first line anti-TB treatment and are not placed on an multi-drug resistant TB (MDR-TB) regimen, and b) relate the treatment outcomes to culture and drug susceptibility patterns (C&DST). DESIGN: Retrospective cohort study using routine programme data and Mycobacterium TB Culture C&DST between July 2008 and December 2009. RESULTS: There were 202 individuals given a re-treatment regimen and included in the study. Overall treatment outcomes were: 68 (34%) with treatment success, 84 (42%) failed, 36 (18%) died, 13 (6.5%) defaulted and 1 transferred out. Treatment success for category I and II failures was low at 37%. In those with positive cultures, 81 had pan-sensitive strains with 31 (38%) showing treatment success, while 61 had drug-resistance strains with 9 (15%) showing treatment success. In 58 patients with negative cultures, 28 (48%) showed treatment success. CONCLUSION: Treatment outcomes of patients who fail a first-line anti-TB treatment and who are not placed on an MDR-TB regimen are unacceptably poor. The worst outcomes are seen among category II failures and those with negative cultures or drug-resistance. There are important programmatic implications which need to be addressed.